Flexion Therapeutics, Puma Biotechnology, and Portola Pharmaceuticals are clinical-stage companies without any revenue producers on the market, but that could change soon. The Food and Drug Administration is expected to issue go/no-go decisions on drugs developed by each of these companies in the coming months, and if they get an OK, it could move the needle significantly for investors.
Overcoming pain
On Oct. 6, the FDA is scheduled to either approve or reject Flexion Therapeutics’ novel therapy for treating knee pain caused by osteoarthritis. If approved, Zilretta will provide doctors and patients with a non-opioid therapy that may work better in patients than quarterly corticosteroid injections.
